U.S. markets open in 1 minute

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Precio retrasado. Divisa en USD.
Añadir a la lista de seguimiento
13.18+0.09 (+0.69%)
Al cierre: 04:00PM EDT
13.17 -0.01 (-0.08%)
Antes de la apertura del mercado: 09:27AM EDT

Teva Pharmaceutical Industries Limited

124 Dvora HaNevi’a Street
Tel Aviv 6944020
Israel
972 3 914 8213
https://www.tevapharm.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo35,001

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Eric DrapeExecutive Vice President of Global Operations1.91MN/D1962
Mr. Mark SabagExecutive Vice President of International Markets Commercial1.92MN/D1971
Mr. Richard D. FrancisPresident, CEO & DirectorN/DN/D1968
Mr. Amir WeissSenior VP & Chief Accounting OfficerN/DN/D1977
Ran MeirHead of Investor RelationsN/DN/DN/D
Kathleen VeitSenior Vice President, Global Compliance & Ethics OfficerN/DN/DN/D
Mr. Kevin C. MannixSenior Vice President of Investor RelationsN/DN/DN/D
Advocate Nir BaronSenior VP & Chief Internal AuditorN/DN/DN/D
Mr. Richard Gordon DaniellExecutive Vice President of European CommercialN/DN/D1967
Mr. John NasonPresident of Teva Active Pharmaceutical Ingredients (TAPI) & Biologics OperationsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Gestión corporativa

La calificación ISS Governance QuickScore de Teva Pharmaceutical Industries Limited a partir del 1 de abril de 2024 es 5. Las puntuaciones principales son Auditoría: 9; Junta: 3; Derechos del accionista: 5; Compensación: 4.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.